About Index Trending news
Analyze
Top 50 Pricing
Nektar Therapeutics

Nektar Therapeutics

Work at Nektar Therapeutics? Add yourself to this profile

Nektar Therapeutics

Nektar is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates designed to improve the benefits of drugs for patients.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO equity
$20,000,000
Venture capital
$25,000,000
Employees

Team size

500+
Locations
$20,000,000 Post-IPO equity
Xconomy

Nektar Therapeutics Gets $20M in Daiichi Deal For Breast Cancer Drug

The Motley Fool

Why Nektar Therapeutics Inc Is Dropping Today

The Motley Fool

Here's Why Nektar Therapeutics Inc. Rose 19% in March

The Motley Fool

Why Nektar Therapeutics Skyrocketed 30% Higher in October --

Stock markets Health